论文部分内容阅读
目的探讨高精度持续循环腹腔热灌注(continuous hyperthermic peritoneal perfusion chemotherapy,CHPPC)联合新辅助化疗在提高初次肿瘤减灭术疗效不佳的晚期卵巢癌患者二次肿瘤细胞减灭术成功率及疗效中的作用。方法初次肿瘤减灭术疗效不佳晚期卵巢癌患者60例,随机分为对照组28例和观察组32例,对照组应用PT(紫杉醇+奥沙利铂)方案化疗3个周期后行二次肿瘤细胞减灭术;观察组初次肿瘤细胞减灭术后第1,3,5天行CHPPC,1周后行PT化疗3个周期,然后行二次肿瘤细胞减灭术,比较2组二次肿瘤细胞减灭术有效率及疗效,并观察不良反应发生情况。结果观察组二次肿瘤细胞减灭术有效率(89.29%)高于对照组(75.00%)(P<0.05),治疗总有效率(82.14%)高于对照组(62.50%)(P<0.05),不良反应发生率(53.57%)与对照组(53.12%)比较差异无统计学意义(P>0.05)。结论 CHPPC联合新辅助化疗用于初次肿瘤减灭术疗效不佳的晚期卵巢癌患者,可提高二次肿瘤细胞减灭术有效率及疗效,且不增加不良反应发生率。
Objective To investigate the efficacy and safety of high-precision continuous hyperthermic peritoneal perfusion chemotherapy (CHPPC) plus neoadjuvant chemotherapy in improving the success rate of secondary cytoreductive surgery and its efficacy in patients with advanced ovarian cancer who have poor response to primary tumor ablation effect. Methods Sixty patients with poor prognosis of advanced ovarian cancer were randomly divided into control group (n = 28) and observation group (n = 32). The control group was treated with PT (paclitaxel + oxaliplatin) The patients in the observation group were treated with CHPPC on the 1st, 3rd, 5th day after the initial cytoreductive surgery. Three cycles of PT chemotherapy were performed one week later, and the second cytoreductive surgery was performed. The second group of tumor cells Reduction of surgery efficiency and efficacy, and to observe the occurrence of adverse reactions. Results The effective rate of secondary cytoreductive surgery (89.29%) in observation group was higher than that in control group (75.00%) (P <0.05), and the total effective rate was 82.14% (62.50%) in observation group ), The incidence of adverse reactions (53.57%) compared with the control group (53.12%) was no significant difference (P> 0.05). Conclusion CHPPC combined with neoadjuvant chemotherapy for patients with advanced ovarian cancer who have poor response to primary tumor ablation can improve the efficiency and efficacy of secondary cytoreductive surgery without increasing the incidence of adverse reactions.